PRACTECAL-PKPD Sub Study

Pulmonary Tuberculosis Clinical Trial

— PRACTECAL-PKPD  

Official title:

Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04081077
• Other study ID #: PRACTECAL-PKPD
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: August 6, 2019
• Est. completion date: September 30, 2022

Study information

• Verified date: May 2021
• Source: Medecins Sans Frontieres, Netherlands
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the TB-PRACTECAL trial investigational regimens and their respective treatment outcomes.

Description:

PRACTECAL-PKPD is a sub-study of the main TB-PRACTECAL phase II-III trial for the treatment of biologically confirmed pulmonary multi drug or extensively drug-resistant TB (M/XDR-TB). TB-PRACTECAL is a multicentre, open label, phase 2-3 randomised controlled trial evaluating 6 months, exclusively oral regimens containing bedaquiline (B), pretomanid (Pa), linezolid (Lzd) +/- moxifloxacin (Mfx) or clofazimine (Cfz) for the treatment of microbiologically confirmed pulmonary M/XDR-TB.

Primary objective Measure the plasma concentrations of pretomanid, linezolid, bedaquiline, clofazimine and moxifloxacin in a sub-set of patients in the TB-PRACTECAL trial and using population pharmacokinetic (PK) models, estimate the population exposure metrics (minimum plasma concentration (Cmin), mean plasma concentration (Cmean), maximum plasma concentration (Cmax), plasma concentration versus time curve (AUC)) for the individual drugs in the TB-PRACTECAL trial.

Secondary objectives Develop a population pharmacodynamic model to explore the relationship between drug exposure, baseline minimum inhibitory concentrations and both mycobacteriological and clinical treatment success Develop a population pharmacodynamics model and identify PK parameters that are associated with treatment emergent toxicity Explore covariates specific to the regimens and study population Use results of above objectives to develop a hypothesis on the optimal dosing of linezolid and clofazimine Explore the pharmacogenomic factors associated with efficacy and toxicity of the investigational drugs Analyse adherence/exposure to the investigational regimen(s) by analysing anti-TB drug levels in small hair samples Assess the potential of using hair drug levels to develop safety and efficacy pharmacodynamic models Conduct clinical validation of a dried blood quantification method using volumetric absorptive microsampling.

Procedures:

4 ml (vacutainer tube, lithium heparin) of blood will be collected from the hand, forearm or antecubital vein at each sampling occasion and moment for the PK. The sampling occasions are on Day 1, Weeks 8, 12, 16, 20, 24, 32 and 72. On Day 1, blood will be collected just before drugs intake, then 2 and 23 hours after drugs intake. On week 8, blood will be collected just before drugs intake, then 6.5 and 23 hours post dose. At weeks 12, 16, 20 and 24 the blood will be collected within 30 minutes before taking the dose. Samples from week 32 and 72 will be collected whenever feasible after the patients have completed their treatment so blood collection is not relative to drug intake on that occasion. These have been included to capture the elimination phases of the drugs which have long terminal half-lives.

A subgroup of patients will also participate to the clinical validation study of a dried blood quantification method using volumetric absorptive microsampling. 2ml of blood and a drop of blood from the finger tips will be collected at the following sampling occasions: day 1, week 8, 12 and 16.

In the small hair study, a small thatch of hair will be cut as close as possible to the scalp from the occiput at weeks 8, 16, 24, 32 and 72.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 240
• Est. completion date: September 30, 2022
• Est. primary completion date: September 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Main study inclusion criteria*:

Patients eligible for inclusion in the trial must fulfil all of the following criteria:

• Male or female subjects aged 15 years of age or above, regardless of HIV status;

• Microbiological test (molecular or phenotypic) confirming presence of M. tuberculosis;

• Resistant to at least rifampicin by either molecular or phenotypic drug susceptibility test;

• Completed informed consent form (ICF);

Main study exclusion criteria:

• Known allergies, hypersensitivity, or intolerance to any of the study drugs;

• Pregnant or breast-feeding; or unwilling to use appropriate contraceptive measures

• Liver enzymes >3 times the upper limit of normal;

• Any condition (social or medical) which, in the opinion of the investigator, would make study participation unsafe;

• Taking any medications contraindicated with the medicines in the trial; QTcF > 450ms;

• One or more risk factors for QT prolongation (excluding age and gender) or other uncorrected risk factors for TdP;

• History of cardiac disease, syncopal episodes, symptomatic or asymptomatic arrhythmias (with the exception of sinus arrhythmia);

• Any baseline biochemical laboratory value consistent with Grade 4 toxicity.

• Moribund

• Known resistance to bedaquiline, pretomanid, delamanid or linezolid.

• Prior use of bedaquiline and/or pretomanid and/or linezolid and/or delamanid for one or more months.

• Patients not eligible to start a new course of MDR-TB/XDR-TB treatment according to local protocol, including but not limited to:

• currently on MDR-TB treatment for more than 2 weeks (and not failing)

• unstable address

• loss to follow-up in previous treatment with no change in circumstance and motivation.

• Tuberculous meningoencephalitis, brain abscesses, osteomyelitis or arthritis.

*PKPD inclusion/exclusion:

• Adult patients (aged 18 years or above) recruited into the investigational arms of the TB-PRACTECAL trial in the approved sites.

• Willing to sign the sub-study informed consent form after agreeing to the additional blood draws.

Related Conditions & MeSH terms

• Extensively Drug-Resistant Tuberculosis
• Multi-drug Resistant Tuberculosis
• Pulmonary Tuberculosis
• Tuberculosis
• Tuberculosis, Multidrug-Resistant
• Tuberculosis, Pulmonary

Intervention

Drug:
• Bedaquiline
Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
• Pretomanid
Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
• Moxifloxacin
Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
• Linezolid
Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
• Clofazimine
Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.

Locations

Country	Name	City	State
Belarus	Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital	Minsk
South Africa	King DinuZulu Hospital	Durban	KwaZulu-Natal
South Africa	THINK Clinical Trial Unit, Hillcrest	Durban	KwaZulu-Natal
South Africa	Helen Jospeh Hospital	Johannesburg	Gauteng
South Africa	Doris Goodwin Hospital	Pietermaritzburg	KwaZulu Natal

Sponsors (16)

Lead Sponsor

Collaborator

Medecins Sans Frontieres, Netherlands

Drugs for Neglected Diseases, eResearch Technology, Inc., Global Alliance for TB Drug Development, Hackensack Meridian Health, London School of Hygiene and Tropical Medicine, Ministry of Health, Republic of Uzbekistan, Ministry of Public Health, Republic of Belarus, Minsk Republican Research and Practical Centre for Pulmonology and Tuberculosis, Swiss Tropical & Public Health Institute, THINK TB & HIV Investigative Network, University College, London, University of California, San Francisco, University of Liverpool, Wits Health Consortium (Pty) Ltd, World Health Organization

Countries where clinical trial is conducted

Belarus,  South Africa, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetic: Cmax	Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate Peak Plasma Concentration (Cmax)	72 weeks
Primary	Pharmacokinetic: AUC	Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the area under the plasma concentration versus time curve (AUC)	72 weeks
Primary	Pharmacokinetic: T1/2	Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the elimnation half life (T1/2)	72 weeks
Primary	Pharmacokinetic: Tmax	Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the time present at maximum plamsa concentration (Tmax)	72 weeks
Primary	Pharmacodynamics: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Number of patients with serious adverse events (SAE), adverse events of special interest (AESI) and other AEs with their respective severity grading.	72 weeks
Primary	Pharmacodynamics: Culture Conversion 24 weeks post treatment [Efficacy]	Percentage of patients with culture conversion in liquid media at 24 weeks post randomisation	24 weeks